ArticleThe Journal of clinical investigation2004
Innate immunity dictates cytokine polarization relevant to the development of pulmonary fibrosis.
Article in The Journal of clinical investigation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Meta-analysis of genetic programs between idiopathic pulmonary fibrosis and sarcoidosis.PloS one · 2013Pooled it
- CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis.Respiratory research · 2005Trial
- Adoptive Transfer of T Cells as a Potential Therapeutic Approach in the Bleomycin-Injured Mouse Lung.The journal of gene medicine · 2025Article
- Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension.Immunity, inflammation and disease · 2023Review
- The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.International journal of molecular sciences · 2019Review
- Protective role of NKT cells and macrophage M2-driven phenotype in bleomycin-induced pulmonary fibrosis.Inflammopharmacology · 2018Article
- Natural killer cells from patients with chronic rhinosinusitis have impaired effector functions.PloS one · 2013Article
- Transgenic modelling of cytokine polarization in the lung.Immunology · 2011Review
- Natural killer cells in infection and inflammation of the lung.Immunology · 2009Review
- Inflammatory mechanisms in the lung.Journal of inflammation research · 2009Article
- Mechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders.Neuropsychiatric disease and treatment · 2007Article
- Maintenance of radiation-induced intestinal fibrosis: cellular and molecular features.World journal of gastroenterology · 2007Review
- Galectin-3 regulates myofibroblast activation and hepatic fibrosis.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Interleukin-12 is not essential for silicosis in mice.Particle and fibre toxicology · 2006Article
- Gene fusion of IL7 involved in the regulation of idiopathic pulmonary fibrosis.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
New data support the importance of the innate immune response in the resolution or progression of pulmonary fibrosis. The presence of CXC chemokine receptor 3-expressing cells, specifically pulmonary NK cells, is necessary to produce IFN-gamma. This is critical in the polarization of the immune response to injury toward a favorable Th1 response and resolution. In contrast, a Th2 response is associated with progressive fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.